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The hexameric AAA-ATPase Drg1 is a key factor in eukaryotic ribosome biogenesis and
initiates cytoplasmic maturation of the large ribosomal subunit by releasing the shuttling
maturation factor Rlp24. Drg1 monomers contain two AAA-domains (D1 and D2) that act in a
concerted manner. Rlp24 release is inhibited by the drug diazaborine which blocks ATP
hydrolysis in D2. The mode of inhibition was unknown. Here we show the first cryo-EM
structure of Drg1 revealing the inhibitory mechanism. Diazaborine forms a covalent bond to
the 2′-OH of the nucleotide in D2, explaining its specificity for this site. As a consequence,
the D2 domain is locked in a rigid, inactive state, stalling the whole Drg1 hexamer. Resistance
mechanisms identified include abolished drug binding and altered positioning of the
nucleotide. Our results suggest nucleotide-modifying compounds as potential novel inhibitors
for AAA-ATPases.
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The evolutionarily conserved protein family of AAA-proteins plays key roles in fundamental cellular path-ways, including protein homeostasis (e.g., p97/Cdc48,
reviewed in refs. 1–3), chromatin remodeling (e.g., RuvBL1/24), or
vesicle trafficking (e.g., NSF, reviewed in ref. 5). AAA-proteins act
as specialized macromolecular machines that catalyze unfolding
of proteins targeted for degradation or remodel whole macro-
molecular complexes (recently reviewed in ref. 6). Due to their
pivotal roles, AAA-ATPases emerged as druggable targets in
recent years. Several compounds modulating protein homeostasis
by targeting the AAA-ATPase p97 were developed as potential
treatments for tumors or neurodegenerative diseases, with one
inhibitor reaching phase I clinical trials (reviewed in7). However,
the number of selective AAA-ATPase inhibitors is limited, and
extensive research is ongoing to broaden the spectrum of
applicable inhibition mechanisms.
AAA-ATPases also fulfill crucial roles in ribosome biogenesis, a
pathway that recently also entered the focus of chemical biology
as a promising target (recently reviewed in ref. 8). The formation
of the two ribosomal subunits is a long cascade of consecutive
maturation steps with the aim to correctly process and assemble
the ribosomal RNAs with all ribosomal proteins. This maturation
cascade is driven by the concerted actions of more than 250
maturation factors that temporarily associate with the pre-
ribosomal particles and dissociate when their task is fulfilled
(recently reviewed by Klinge and Woolford9). Ribosome bio-
genesis is the most energy-consuming cellular process and is
tightly coordinated with cell cycle control and proliferation. Due
to tight links between ribosome biogenesis and proliferation of
tumor cells, this pathway is regarded as one of the most pro-
spective future targets for anti-tumor chemotherapy (reviewed in
refs. 8,10,11). Astonishingly, until recently, where a first non-
targeted approach to screen for ribosome biogenesis inhibitors
was described12, only two inhibitors were known to specifically
target the maturation of ribosomal subunits. Both of these inhi-
bitors target AAA-proteins. Rbin1 was identified as an inhibitor
of the Dynein-like AAA-ATPase Mdn113, while diazaborine
targets the hexameric type II AAA-ATPase Drg1 which is highly
related to p9714–16.
Drg1 is a key factor in late eukaryotic ribosome biogenesis and
binds to pre-60S particles, the precursors of the large ribosomal
subunit, as soon as they are exported from the nucleus into
the cytoplasm (Fig. 1a17–20). Drg1 recognizes its substrate protein,
the shuttling maturation factor Rlp24, on the pre-ribosomal
particle via an unstructured, highly charged C-terminal extension
of Rlp2419,21. Interaction with this Rlp24C-domain stimulates the
ATPase activity of Drg1 and this accelerated enzymatic activity
drives the extraction of Rlp24 from the pre-ribosome.
Drg1 contains two conserved AAA-ATPase domains (D1 and
D2) per monomer and a non-catalytic N-terminal domain.
Although both AAA-domains provide in vitro ATPase activity,
they contribute differently to the release of Rlp2419,21. While ATP
hydrolysis in D2 is essential to extract Rlp24 from the pre-60S
particle, nucleotide hydrolysis in D1 is dispensable for growth.
However, nucleotide binding to D1 is the major determinant for
the oligomeric state of Drg1 and is essential19.
Deep insights into the operating principle of Drg1 as well as its
role in ribosome biogenesis were achieved with help of the spe-
cific small-molecule inhibitor diazaborine21–23. Diazaborine
inhibits the ATPase activity of Drg1 and thereby prevents the
release of Rlp24 from the particle in vivo and in vitro. As this step
is a strict prerequisite for all downstream maturation events of the
pre-60S particle, inhibition of Drg1 fully blocks cytoplasmic steps
of pre-60S subunit maturation and leads to an entrapment of all
known shuttling proteins in the cytoplasm19,21,22,24. Drg1 exhi-
bits a low basal ATPase activity, which mainly originates from the
D1 domain19. The analysis of Drg1 Walker B variants, defective
in ATP hydrolysis in D1 or D2, showed that diazaborine exerts
only little effect on the basal activity of Drg1, but strongly affects
the stimulated ATP hydrolysis in D221. Mutations causing
resistance to diazaborine are exclusively found in or near the D2
nucleotide-binding pocket15,21. Together, these data suggest that
diazaborine specifically targets the D2 domain of Drg1. However,
due to the lack of structural data, the molecular mechanism of
inhibition was unknown.
Here, we present the first high-resolution (3.4 Å) cryo-EM
structure of the Drg1 hexamer in complex with its inhibitor
diazaborine. This structure reveals the exact binding mode of the
inhibitor in the D2 nucleotide-binding pocket and allows us to
pinpoint its mechanism of inhibition as well as mechanisms
leading to diazaborine resistance.
Results
Diazaborine forms a covalent adduct with the nucleotide in the
D2 ATPase domain of Drg1. To unravel the mechanism of Drg1
inhibition by diazaborine, we collected a single-particle cryo-EM
dataset of full-length wild-type Drg1 in the presence of the
inhibitor thieno-diazaborine derivative 2b18 (short diazaborine
from hereon, ref. 25). To stabilize the complex for structural
investigation, we added ATPγS since hexamer formation of Drg1
is strictly dependent on the presence of nucleotides and is
enhanced by this slow hydrolyzing ATP-analog15,19. Accordingly,
we observed a homogeneous population of hexameric Drg1
particles resulting in a 3.4 Å map (Supplementary Table 1 and
Supplementary Fig. 1). Based on this map, we built a model
comprising the D1 and D2 domains of all six monomers (amino
acids 239–780) but lacking the N-domains (Fig. 1b).
Due to their intrinsic flexibility, the N-domains of all monomers
are less well defined but uniformly found in an elevated position
which presumably reflects the loading state of D1 with ATPγS
analogously to cryo-EM data of p9726. The D1 and D2 AAA-
domains form two stacked rings and all nucleotide-binding pockets
are occupied with ATPγS. Without imposing symmetry during
image processing, the AAA-domains in this structure are arranged
highly symmetrically around the open central pore similar to
substrate-free structures of related AAA-ATPases like Cdc4827 or
VAT28. The two ATPase domains of Drg1 adopt a characteristic
classical AAA-domain architecture each containing a larger N-
terminal α/β subdomain and a smaller, C-terminal α-helical
subdomain exhibiting extensive structural similarity to p97 (pdb:
5FTN26) with an rmsd value of 3.5 Å (Supplementary Fig. 2).
Minor differences are that in Drg1 the short D1 helix 13 of p97 is
missing and helix 12′ in D2 is significantly longer (annotation
according to DeLaBarre and Brunger29). The Walker A/Walker B
motifs and the Arginine fingers are well resolved and highly
conserved. The catalytic glutamate in Walker B of D1 is positioned
in closer proximity to the γ-phosphate in Drg1 than in p97
(Supplementary Fig. 2b), possibly suggesting a more active D1 ATP
hydrolysis. In contrast, the catalytic residues in the D2 domain are
positioned highly similar in both proteins (Supplementary Fig. 2c).
As expected from the highly symmetric organization of the
hexamer, the central pore of Drg1 is devoid of any substrate
polypeptide chain. As a consequence, the pore loops are more
flexible and not well resolved in our structure. Interestingly, the
pore loops of the D1 domain are significantly better resolved than
those of the D2 domain and thus might be less flexible
(Supplementary Fig. 2d). Since the N-domains did not allow
model building, we rigid body fitted a homology model of the Drg1
N-domain (Supplementary Fig. 2e). This showed that it adopts the
same bipartite subdomain organization (NN and NC) as the N-
domain of p97 (Supplementary Fig. 2f).
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In agreement with biochemical and genetic data21, we located
diazaborine inside the D2 nucleotide-binding pocket (Fig. 2a), but
not in D1, which explains the specific inhibition of ATP
hydrolysis in D2. The Drg1 map revealed a clear density in the
nucleotide-binding pocket of all six D2 domains which is neither
covered by the protein nor by the bound nucleotide. Diazaborine
is thereby mounted on top of the bound nucleotide ATPγS, and a
continuous density allowed modeling of a covalent inhibitor-
nucleotide adduct (diazaborine-ATPγS; Fig. 2b). The covalent
bond is formed between the highly reactive boron atom of the
inhibitor and the 2′-OH group of the ribose moiety of the
nucleotide (Fig. 2c). This covalent diazaborine-nucleotide adduct
is reminiscent of a similar adduct formed by diazaborine and
NAD+ in the enoyl-acyl carrier protein reductase FabI, the
bacterial target of diazaborine30–32. The bipartite density of the
inhibitor moiety inside the Drg1 D2 domain strongly resembles
the electron density of diazaborine bound to the bacterial protein
























Fig. 1 Cryo-EM structure of the AAA-ATPase Drg1 in complex with diazaborine. a Diazaborine inhibits the AAA-ATPase Drg1 and thereby blocks the
release of Rlp24 which is the first cytoplasmic maturation event of the large ribosomal subunit (60S). b 3.4 Å cryo-EM map of a diazaborine bound Drg1
hexamer in top and side view. The D1 and D2 AAA-domains of the six monomers are symmetrically arranged around the open central pore reflecting a
substrate-free, inactive state of the AAA-ATPase. The N-domains are less well resolved due to their intrinsic flexibility which reflects the nucleotide-
binding state of the D1 nucleotide-binding pocket. c The atomic model comprises amino acids 239–780 of each of the six monomers (A–F) fully covering
both AAA-domains but lacking the N-domains.
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aliphatic chain is not clearly resolved in our structure due to the
predicted orientational flexibility of this part of the inhibitor
(Supplementary Fig. 3a).
Since the binding pocket is formed at the interface between two
monomers, residues from adjacent monomers can potentially be
involved in the binding of one diazaborine molecule. At a closer
look at the surrounding of the bound diazaborine-ATPγS adduct,
it is positioned at the opening of the D2 nucleotide-binding
pocket with only very few amino acid residues (e.g., V725) in
direct contact with the inhibitor in this conformation (Supple-
mentary Fig. 3b). The inhibitor moiety mostly faces the
surrounding bulk solvent rather than making extensive contacts
to Drg1 residues. Stable binding of the inhibitor-nucleotide
adduct is therefore mainly accomplished by the firmly bound
nucleotide moiety which is, in contrast to the inhibitor, tightly
enclosed by multiple residues of the binding pocket, including
residues of the highly conserved Walker A motif. This is
consistent with the finding that the inhibitor shows no binding
to Drg1 in the absence of nucleotides in D2 (as in the Drg1-KA2
(Walker A) variant described in ref. 21).
To confirm that diazaborine is bound via the 2′-OH group of
the nucleotide, we used 2′-deoxy-ATP (dATP) as nucleotide
lacking this OH group, and tested diazaborine binding to Drg1 in
our in vitro DSF setup. Indeed, in the presence of dATP,
diazaborine did not cause a change of the melting temperature
although dATP itself had a similar effect on the stability of Drg1
as ATP (Fig. 2d). Consistently, in the presence of dATP,
diazaborine did not affect the ATPase activity of Drg1 (Fig. 2e).
Accordingly, consistent with our structural prediction, the 2′-OH
group of the nucleotide is essential for diazaborine binding. Very
likely, this bulky adduct will also dissociate more slowly from the
protein than the authentic nucleotide. In line with this suggestion,
the drug slows down the dissociation of Drg1 from Rlp24C by a
factor of two, as determined by SPR measurement (Supplemen-
tary Fig. 3c and d). This might explain, why diazaborine acts as an
efficient inhibitor albeit the affinity to the target is low21.
In summary, the inhibition of the Drg1 D2 AAA-domain is the
result of a covalent modification of the bound nucleotide by the
inhibitor. Diazaborine therefore represents the first known
nucleotide-modifying inhibitor of a AAA-ATPase.
Diazaborine locks the D2 domain in an inactive state. AAA-













































































Fig. 2 Diazaborine forms a covalent adduct with the nucleotide in the D2 AAA-domain of Drg1. a All six nucleotide-binding pockets of the D2 AAA-
domains of Drg1 contain a continuous density representing a covalent adduct between the bound nucleotide ATPγS and the inhibitor diazaborine. b The
isolated density of the inhibitor-nucleotide adduct in D2. c The covalent bond is formed between the boron atom of diazaborine and the 2′-OH group of the
nucleotide ribose moiety. d Diazaborine cannot bind to Drg1 in the presence of 2′-deoxy-ATP (dATP) due to the lacking 2′-OH group demonstrated by DSF
measurements. The averaged derivative curves (dF/dT) of the melting curves of four measurements from two biological replicates are shown (n= 4). e
Diazaborine does not affect the ATPase activity of Drg1 when dATP is used as cofactor. The stimulated ATPase activity of Drg1 was measured in the
presence of either 1 mM ATP (cyan and blue) or dATP (orange and red). The activity was stimulated by the HIS6-tagged C-terminal fragment (amino acids
147–199) of the substrate protein Rlp2419. Diazaborine was added to a final concentration of 100 µg/ml. Means and standard deviations are shown from
four individual measurements (n= 4). The specific activity (µmol ATP/h/mg Drg1) was calculated and normalized to the uninhibited activity in the
presence of ATP (=100%). Source data for 2d and 2e are provided as a Source data file.
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individual subunits and domains. These changes are a result of
the ATP hydrolysis cycle and are essential for substrate proces-
sing. In order to better understand the inhibitory effect of dia-
zaborine on the activity of Drg1, we performed a 3D variability
analysis of our cryo-EM data to visualize the conformational
flexibility of the hexamer. This analysis revealed coordinated
movements of the D1 and N-domains within the whole hexamer
(Fig. 3 and Supplementary Movie 1). Strikingly, the diazaborine
loaded D2 ring, remained in a rigid state, not indicating coordi-
nated movements with the rest of the hexamer. Due to this
rigidity and tilting of the D1 domain, the D1–D2 linker is sig-
nificantly bent demonstrating its role as a flexible hinge between
the AAA-domains. The locking of the D2 domain in an inactive
state and the failure to communicate with the D1 domain,
the main determinant of oligomerization, is likely the reason for
the stabilizing effect of diazaborine on the hexameric form of
Drg1 as demonstrated by Size Exclusion Chromatography (Sup-
plementary Figs. 4 and 5).
Thus, binding of the inhibitor to D2 presumably restrains the
conformational flexibility of this domain and thereby impairs
the functionality of the whole hexamer. To further investigate
the impact of the inhibitor on the functioning of the protein, we
analyzed how the inhibitor-nucleotide adduct interferes with
the transition of Drg1 from the symmetric, inactive form into
an asymmetrically arranged, staircase-like substrate-engaged
and active state (reviewed in ref. 33). Since a substrate-bound
structure of Drg1 is not available, we used the recently
published structure of the close relative Cdc4827 to build a
Drg1 homology model in an active staircase-like conformation
and positioned the diazaborine-ATPγS adduct based on a
superposition with the ADP molecules present in Cdc48.
Strikingly, while the nucleotide-binding pocket in our sym-
metric structure can easily accommodate the inhibitor (Fig. 3b),
the pockets in the active-state model are not compatible with
the positioning of the inhibitor-nucleotide adduct as exempli-
fied for the binding site between the D/E protomers in Fig. 3c.
Here, the diazaborine moiety clashes strongly with α-helix 7 of
the D2 domain indicating that the presence of diazaborine
impairs the conformational transition to the active state. The
predicted clashes were corroborated by a cavity analysis with
which we assessed the available space in the binding pocket of
the model (Fig. 3d).
Exchanges in the D2 binding pocket cause resistance to dia-
zaborine. To uncover the mechanisms leading to diazaborine
resistance, we generated a set of resistant Drg1 variants by ran-
dom mutagenesis of the full-length DRG1 gene and characterized
the impact of the mutations in vitro and in vivo (Fig. 4). In line
with earlier reported diazaborine resistance mediating exchanges
isolated by non-targeted approaches14,15,21, all newly identified
residues are also located in D2 (Fig. 4a and b). Spot assays
demonstrated that all tested mutants are viable and show inter-
mediate resistance to diazaborine (Fig. 4c).
The individual amino acid exchanges resulted in different levels
of sensitivity to diazaborine. The observed differences in
sensitivity in the spot assays were confirmed by quantitative
measurements in liquid culture to determine the half-maximal
inhibitory concentration (MIC) of diazaborine for the different
mutant strains (Fig. 4d). The strongest resistant phenotype was
observed for the strain expressing the V725E (drg1-1)
exchange14,15,21. Consistent with this phenotype, the purified
Drg1-V725E protein shows no detectable binding of the drug in
DSF measurements21. In our structure, V725 is one of the very
few Drg1 residues directly in contact with the bound inhibitor.
Amino acid exchanges in this position will thus sterically affect
the positioning of the inhibitor. Interestingly, three different
amino acid exchanges of V725 (to E, A, or L), result in resistance
to diazaborine (Fig. 4c and ref. 21). While the substitution of
valine for leucine or glutamate (V725L/E) causes high-level
resistance, the substitution for alanine only causes a slight
increase in drug tolerance. Comparing these three exchanges at
the same position suggests that not only the size but also the
charge might be important for inhibitor binding and/or
preventing formation of the adduct. Thus, valine 725 seems to
play a crucial role in forming the structural environment for
diazaborine binding. Strains expressing the V725E variant show
impaired growth only at very high concentrations compared to
other tested mutant variants. Accordingly, with the concentra-
tions used in this study (up to 100 µg/ml) the drug is highly
specific and does not have additional essential targets in yeast
(Fig. 4c). Inspection of the amino acid sequences of all AAA-
ATPases related to Drg1 in yeast revealed that only Drg1 contains
valine at the respective position (Fig. 4e and Supplementary Fig.
6). The closest relatives of Drg1 in yeast contain alanine
(Rix734–36) or leucine (Cdc483,37) at the particular position, both
of which cause resistance to diazaborine in Drg1. More distantly
related yeast AAA-proteins contain charged or bulky residues (R,
K, E, T, and Q). This finding likely explains the strict selectivity of
diazaborine for Drg1 in yeast. p97, the mammalian orthologe of
Cdc48 contains threonine at this position. Indeed, docking of
diazaborine into the symmetric structure of p97 results in severe
clashes with the inhibitor (Supplementary Fig. 6c).
All other identified mutations affect residues that are not in
contact with the inhibitor in the binding pocket. These residues
are therefore rather expected to influence binding affinities and/or
positioning of the nucleotide which might indirectly affect the
formation of the diazaborine-nucleotide adduct. I692T, for
example, is located beneath the adenine moiety of the bound
nucleotide and an exchange at this position will have a strong
effect on its positioning. Interestingly, L555F and V656A as well
as the previously described C561T exchange in the Walker A
motif21 are located on the opposite side of the diazaborine-
nucleotide adduct, more closely to the phosphate groups of
the nucleotide. Again, these residues cannot directly contact
the inhibitor, but will presumably alter the environment in
the nucleotide-binding pocket including the positioning of the
critical Walker A and B residues and thus also of the nucleotide
(Fig. 4b).
Exchanges in the nucleotide-binding pocket affect diazaborine
binding and basal ATPase activity of Drg1. Since the identified
exchanges resulted in different levels of sensitivity to the inhi-
bitor, we evaluated binding of diazaborine to the purified Drg1
variants by DSF measurements (Fig. 5a). Consistent with our
previous experiments, binding of diazaborine to the Drg1 variants
was indicated by a shift to a higher melting temperature21. This
concentration-dependent shift was used to quantify the binding
affinity of the inhibitor for the individual Drg1 variants. The
V725E as well as the K563A (D2 Walker A) variant were shown
previously to exhibit no detectable binding of diazaborine
in vitro21. All new mutant variants showed a detectable but
strongly reduced affinity for the drug compared to wild-type
Drg1. Based on the measured binding affinities, the tested var-
iants could be classified into two groups with binding affinities in
the µM range (Drg1 wild type and V725A) or very low binding
near the detection limit of the method (L555F, V656A, I692T),
respectively. The V725A variant, which contains an alanine
instead of the glutamate in the highly resistant drg1-1 allele,
caused a twofold reduction of affinity compared to the wild type
which correlates well with the lower level of resistance.
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Fig. 3 Diazaborine prevents Drg1 to adopt an active state. a 3D variability analysis of the cryo-EM data revealed coordinated movements of the D1 and N-
domains visualized by the superposition of two states (red and blue, see also Supplementary Movie 1). These movements visualize the conformational
flexibility of these domains needed to link ATP hydrolysis to mechanical substrate processing. The diazaborine loaded D2 domain is not participating in the
coordinated movements. b Binding pocket of the experimentally determined symmetric structure in two orientations. c Diazaborine does not fit into the
binding pocket of the active-state model. Homology modeling of Drg1 D2 nucleotide-binding pockets in the asymmetric, active state based on a structure of
Cdc48 (pdb-code 6OPC, ref. 27). The adduct was placed in the binding site by superimposing its ribose ring atoms on the corresponding moiety of the
nucleotide (ADP) present in the homology model. The two protomers forming the nucleotide-binding site are shown in pink and light blue. In the binding
pockets of this model, diazaborine severely clashes with α-helix 7. One site is exemplarily shown. d Cavity analysis of the binding pocket of the asymmetric
model. The cavity in the vicinity of ADP is represented as light gray spheres. Larger parts of the diazaborine portion of the adduct not covered by the point
cloud indicate that the inhibitor is incompatible with the available space in the active state of Drg1.
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Accordingly, resistance to diazaborine caused by these exchanges
is the result of altered binding of the inhibitor.
To further explore the effects of the resistance referring
exchanges, we measured their effect on the ATPase activity of the
purified proteins in vitro (Fig. 5b). As the ATPase activity of Drg1
is enhanced by the interaction with the substrate Rlp24, we
measured the basal activity (without Rlp24) and the stimulated
activity (with the stimulating Rlp24C fragment) of Drg119. As
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Fig. 4 Amino acid exchanges in the Drg1 D2 nucleotide-binding pocket cause resistance to diazaborine. a Domain organization of Drg1. Exchanges
causing resistance to diazaborine are colored. Residues highlighted by (*) were identified in this study by random mutagenesis of the DRG1 gene. Additional
exchanges were described previously14,15,21. b Magnified Drg1 D2 binding pocket at the interface between two monomers. Important residues of the
conserved AAA-binding pocket motifs are shown in cyan (Walker A: K563, Walker B: E617, arginine fingers R671 and R674). c Δdrg1 deletion strains
expressing plasmid-borne mutated drg1 alleles were spotted on YPD agar plates containing 0–100 µg/ml diazaborine. d Half-maximal inhibitory
diazaborine concentration (MIC). Δdrg1 deletion strains expressing plasmid-borne mutated drg1 alleles were grown in YPD containing increasing
concentrations of diazaborine. Maximal OD600 values were plotted against the diazaborine concentration and the IC50 was calculated using non-linear
regression. Two biological replicates were each measured in duplicates (n= 4). Means and standard error are shown. Source data are provided as a Source
Data file. e Sequence conservation of the region around V725 critical for diazaborine susceptibility compared to yeast AAA-ATPases exhibiting significant
homology to Drg1. In addition, the human Drg1 orthologue SPATA5, the human Cdc48 orthologue p97 as well as the yeast dynein-like AAA-ATPase Mdn1
were included. The complete sequence alignment of the Drg1 D2 domain and its closest relatives is provided in Supplementary Fig. 6.
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expected, the enzymatic activities of the mutant variants were less
sensitive to diazaborine than the wild-type protein. Strikingly,
L555F, I692T, and V656A caused elevated basal ATPase activities.
This again indicates that residues that affect binding of the drug
might also (or primarily) interfere with the positioning of the
nucleotide. L555F and V656A are positioned near critical residues
of the Walker A and B motifs (K563 and E617) which might
explain the effect on the ATPase activity by altering the
environment in the nucleotide-binding pocket. For I692T and
L555F, the increased basal activity was not inhibited by the drug,
while V656A showed a reduction. The altered activities of
these mutant variants in the absence of diazaborine strengthen
the hypothesis that binding of the inhibitor is strongly linked to
the positioning of the nucleotide inside the binding pocket.
Taken together, small alterations of the architecture of the
binding pocket strongly affect binding of the inhibitor but also
the functionality of the AAA-domain itself. Therefore, resistance
to the drug can only be achieved by a compromise between
preserving the function of the nucleotide-binding pocket and
preventing the covalent modification of the nucleotide.
Discussion
Here, we show that diazaborine covalently modifies the bound
nucleotide in the D2 domain of Drg1. How does this interfere
with the functioning of Drg1? The mechanics of AAA-ATPases
strictly depend on coordinated global conformational changes in
the AAA-domains of the hexamer which are linked to the
nucleotide and substrate binding states (e.g., discussed for p97 in
refs. 6,33,38). Substrate binding leads to the transition of the
hexamer from a symmetric to an asymmetric, staircase-like
structure during which the D2 domain undergoes a slight rotation
and the protomers adopt a more elongated conformation. Our in
silico modeling indicates that these alterations result in clashes
with the diazaborine-nucleotide adduct. Therefore, the presence
of the inhibitor restrains the flexibility of the nucleotide-binding
pocket and as a consequence, the Drg1 D2 domain might not be
able to adopt a fully active state competent for substrate pro-
cessing and ATP hydrolysis. This explains why the ATPase
activity of the D2 domain of Drg1 is severely inhibited by dia-
zaborine, albeit the inhibitor is not positioned in close proximity
to the γ-phosphate groups of the bound nucleotide21.
Coordination of ATP hydrolysis in the D1 and D2 domains of
the hexamer depends on mechanisms communicating the
nucleotide-binding status between the sites. These mechanisms
are also affected by diazaborine. For example, we show that the
inhibitor leads to more stable hexamers, although it does not
target the D1 domain, the ATP loading state of which is the major
determinant for oligomerization (Supplementary Fig. 4). This
shows that the state of the D2 domain is communicated to D1
and influences ATP hydrolysis in this domain. Furthermore, our
previous studies showed that the failure to hydrolyze ATP in D2
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Fig. 5 D2 mutations affect binding of diazaborine and ATPase activity of Drg1. a Drg1 wild type and the indicated mutant variants were purified and drug
binding was measured using DSF assays. Quantification of the melting point shift (ΔTm, means and error bars showing standard deviation from 4 to 6
measurements (n= 4–6)) of Drg1 in dependency of the diazaborine concentration was used to calculate the binding affinity as EC50 ± standard error21.
b The in vitro ATPase activity was measured using the Malachite green phosphate assay. The ATPase activity was determined in the absence (basal
activity) and in the presence of the HIS6-tagged C-terminal fragment (amino acids 147–199) of the substrate protein Rlp24 (stimulated activity). All
samples contained 1 mM ATP. The activities were calculated as specific ATPase activity (μmol ATP/h/mg Drg1) and normalized to the basal activity of the
wild-type protein (dashed red line). Inhibited activity (+Dia) was measured in the presence of 100 µg/ml diazaborine. Error bars represent standard
deviations of means calculated from three biological replicates (n= 3) each measured in triplicate. Source data are provided as a Source data file.
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(Walker B mutation) modulates the D1 domain and increases its
basal activity. In the presence of diazaborine, the modulating
effect cannot be transmitted from D2 to D1, and the basal activity
of the Drg1 D2 Walker B variant is not increased21.
Together, our findings show that diazaborine exerts its effect
not simply by reducing the enzymatic capacity of Drg1, but rather
interferes with fundamental mechanisms that enable the AAA-
ATPase to act as a finetuned multidomain machine.
The identified amino acid exchanges in Drg1 mediating resis-
tance to diazaborine demonstrate that small changes in the che-
mical and structural environment of the ribose 2′-OH of the
bound nucleotide, including charge, size, or hydrophobicity of the
surrounding residues might prevent covalent bond formation.
The potential for the formation of productive near-attack com-
plexes (NACs) in the binding site is dependent on optimal geo-
metric positioning of the reactants39 and is therefore sensitive to
small changes in the binding site introduced by mutations. This
again demonstrates that although the inhibitor does not form
manifold interactions with the surrounding Drg1 residues, it
depends on a highly specific environment to covalently modify
the nucleotide. Due to their strong effects on the positioning of
the nucleotide, possible mutations causing resistance to the drug
are limited to exchanges that do not compromise the function-
ality of the AAA-domain. This could represent an Achilles heel
for nucleotide utilizing enzymes, and therefore, make nucleotide-
modifying inhibitors promising drug candidates for targeting
AAA-ATPases.
Although this diazaborine derivative specifically targets Drg1 in
yeast, there is also a known target of this compound in prokaryotes.
The chemical class of diazaborines was originally investigated as a
new group of antibacterial agents since they proved to be active
against the Enoyl-ACP reductase (FabI) of Escherichia coli and
other Gram-negative bacteria25,30,31. Since FabI belongs to the
short-chain alcohol dehydrogenase family and is involved in bac-
terial fatty acid synthesis, it shares no conserved function or
extensive structural similarity with Drg1, except that both are
nucleotide utilizing enzymes (NADH for FabI and ATP for Drg1).
Diazaborine inhibits both targets by forming a covalently linked
adduct with the nucleotide and can thus only bind when the
binding pocket is loaded with ATP or NAD+ 21,30. Covalent bond
formation is driven by the high reactivity of the boronic acid
group31,32,40. However, in FabI, diazaborine is attached to the ribose
moiety adjacent to the nicotinamide group. This close proximity
results in a stable “face-to-face” stacking of the diazaborine het-
erocycles and the nicotinamide moiety (Supplementary Fig. 7)31,32.
In the Drg1 D2 domain, formation of a similar stabilized structure
is sterically not possible, since the adenine moiety of the nucleotide
is buried in a cavity of the nucleotide-binding pocket. The observed
differences of the formed inhibitor-nucleotide adduct in FabI and
Drg1 confirm that, as a nucleotide-modifying inhibitor, diazaborine
can target structurally different enzymes. Inhibition is possible as
long as a modifiable nucleotide is involved that provides a suitable
hydroxyl group and a structural environment that favors bond
formation by bringing the reaction partners close together allowing
the formation of a NAC. It was not anticipated previously that this
form of inhibition can be applied to AAA-ATPases.
By uncovering the mode of Drg1 inhibition, we revealed a
completely novel inhibitory mechanism for AAA-ATPases. Since
AAA-ATPases emerged as promising targets for clinical treat-
ment of various diseases, including cancer, new inhibitor strate-
gies with uncommon modes of action are urgently needed
(reviewed in refs. 7,41,42). In theory, nucleotide modification is
applicable to all nucleotide utilizing enzymes. Despite the wide
range of potential targets, this mode of inhibition can target
individual enzymes with high specificity and can be expanded to
other AAA-proteins in structure-guided drug design.
Methods
Growth conditions and protein expression. Yeast and bacterial strains used in
this study are listed in Supplementary Table 2, plasmids are listed in Supple-
mentary Table 3. Wild-type GST-Drg1 and mutant variants were overexpressed in
yeast as described19,21. Essentially, the expression strains were inoculated to a
starting OD600 of 0.01 in synthetic dextrose (SD) media lacking uracil, incubated at
30 °C at 110 rpm in baffled flasks, and harvested after 24 h of protein expression
induced by immediate addition of 0.025 µM CuSO4. Strains for MIC determination
and spot assays were grown either in YPD complex medium or for plasmid
maintenance in synthetic dextrose complete medium supplemented with an
appropriate amino acid mix. SD+ all amino acids supplemented with 1 g/l 5-
fluoroorotic acid (5-FOA, Thermo scientific) was used for plasmid shuffle
experiments.
Protein purification. Overexpressed Drg1 was purified as described
previously19,21. Essentially, frozen cells were thawed in lysis buffer (50 mM Tris-
HCl, 150 mM NaCl, pH 7.4, supplemented with 1 mM DTT and 1× complete
protease inhibitor cocktail (Roche)) and disrupted by vigorous shaking in the
presence of 0.6 mm glass beads using a Merckenschlager beadmill. Crude extracts
were incubated for 90 min at 4 °C with GSH-agarose beads (Sigma-Aldrich) for
affinity purification of GST-tagged Drg1 variants. After consecutive buffer washing
steps (3× with lysis buffer plus 1 mM EDTA and 1mM DTT and 1× with elution
buffer plus 1 mM DTT), the protein was eluted in buffers specific for the respective
experiment. Elution was performed by separating Drg1 from the GST-tag via
Prescission protease treatment (Amersham) overnight at 4 °C on a rotator. Protein
concentration was determined using the Bradford assay (Bio-Rad).
Sample preparation for cryo-EM. Purified wild-type Drg1 was eluted by
separation from the GST-tag in cryo-buffer (20 mM HEPES-KOH, 150 mM KOAc,
5 mM Mg(OAc)2, 0.005% Tween-20, 1 mM DTT, pH 7.6). The protein con-
centration was adjusted to 1.75 mg/ml and immediately prior to grid preparation
the sample was supplemented with 2 mM ATPγS and 200 µg/ml (740 µM) thieno-
diazaborine derivative 2b1825. A 4 µl aliquot of the sample was applied to a freshly
glow-discharged (60 s) Quantifoil R1.2/1.3 copper grid, and plunge-frozen in liquid
ethane using a blotting force of 6 for 6–7 s at 4 °C and 100% humidity in an FEI
Vitrobot Mark IV. Grids were stored in liquid nitrogen until data collection.
Cryo-EM imaging settings. Cryo-EM data were collected on a FEI Titan Krios G3i
operated at 300 kV in nanoProbe energy-filtered transmission electron microscopy
(EFTEM) mode at a nominal magnification of ×81,000 (1.07 Å pixel−1) using a
Gatan K3 BioQuantum direct electron detector with a slit width of 20 eV. The
camera was operated in counting mode using hardware binning and dose frac-
tionation, the total dose of 60 e–/Å2 being divided into 54 images, while the total
exposure time was 4.84 s. The dataset was acquired using SerialEM43 with an active
beam tilt/astigmatism compensation, which shot nine holes once per stage
movement.
Image processing. Image processing was mostly performed in Cryosparc v3.044.
Motion correction was performed by patch motion correction. The CTF of the
micrographs was determined using the patch CTF module. The micrographs were
individually inspected using the manually curate exposures function. 2,373
micrographs were discarded due to low image quality, ice contamination or other
problems, resulting in 2,589 micrographs for particle picking. Initial 2D classes
generated from manually picked particles were used for template picking resulting
in an initial set of 1,152,861 particles. After multiple rounds of 2D classification,
374,782 particles were used for ab initio modeling in Cryosparc. The particles were
transferred to RELION using pyEM45 followed by 3D classification, and 3D
refinement and post processing in RELION v3.046. Finally, the Drg1-diazaborine
map was processed using DeepEMhancer47. Conformational heterogeneity in the
final particle population was detected and visualized using the 3D variability tool
included in Cryosparc V3.048. Software and algorithms for image processing and
model building are also listed in Supplementary Table 4.
Model building and refinement. For model building, an initial homology model
of full-length wild-type Drg1 was generated with the “Phyre2 web portal for protein
modeling, prediction, and analysis”49 based on structures of the related AAA-
ATPase p97. The well-resolved density of the AAA-domains allowed modeling of
residues 239–780 for each of the six monomers, while the N-domains are not
included in the model. Model building was performed in Coot v0.9.250 and Rosetta
v3.0 using an established workflow51, followed by real-space refinement using
Phenix v1.18.2-387452. For refinement of the full covalent diazaborine-ATPγS
adduct, geometric restraints (.cif and .params file) were applied to allow the boron
atom to adopt and preserve the tetrahedral state during real-space refinement. A
comparative model of the active conformation of Drg1 was build using modeler53
within ChimeraX using pdb 6OPC27 as template (with a sequence identity of 45%).
The available space for the inhibitor cavities in the vicinity of ADP molecules
present in the homology model was calculated using the cavity analysis and
comparison program CavMan (available from Innophore GmbH, www.innophore.
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com) employing the LIGSITE algorithm54 with a cutoff-value of 5. For visual
representation UCSF Chimera v1.1555 and ChimeraX v1.1.156 were used.
In silico flexibility estimation of thieno-diazaborine 2b18. A conformational
analysis of the used diazaborine derivative was performed using the conformational
search module of the program MacroModel from the Schrödinger molecular
modeling package (available from Schrödinger, Inc., www.schrodinger.com). For
Figure S2a, 62 unique conformers (with a maximum rmsd of 0.5 Å) were super-
imposed using the atoms of the diazaborinine moiety.
Size exclusion chromatography. For size exclusion chromatography (SEC), the
Drg1 variants were purified with some variations. Indicated samples were purified in
the presence of 5 mM of the respective nucleotide (ATP, ATPγS) and/or 200 µg/ml
diazaborine. The nucleotide and/or diazaborine was added to the lysis, binding, and
elution buffer (20mM HEPES-KOH, 150mM KOAc, 5 mM Mg(OAc)2, 0.1%
Tween-20, 1 mM DTT, pH 6.8). SEC injection samples containing 2 mg of the
respective protein variant were prepared in 1,050 µl elution buffer. For proteins that
were purified in the presence of nucleotide and/or diazaborine, the respective
substance was also added to the injection sample. After high-speed centrifugation at
20,000 × g at 4 °C for 15min, the supernatant was subjected to a 1 ml injection loop
for FPLC analysis (UPC 900, Amersham). The size exclusion column (HiLoad 16/60
Superdex 200 prep grade by GE Healthcare) was equilibrated with three column
volumes of elution buffer (20mM HEPES-KOH, 150mM KOAc, 5 mM Mg(OAc)2,
0.1% Tween-20, pH 6.8). The parameters for the FPLC were set to 1–1.5 ml/min
flow rate with a pressure limit of 0.59MPa and selected fractions (fraction number
23–50) with a volume of 1.6 ml each were collected after UV-detection at 280 nm.
The total elution volume was 120ml. The eluted proteins were concentrated by
TCA precipitation and ~1/10 of the fractions were loaded on SDS-PAGE and
stained with Coomassie.
Surface plasmon resonance. The SPR measurements were performed on a Bia-
core X100 (GE Healthcare/Cytiva). 200 RU of the purified GST-Rlp24C fragment
were immobilized as ligand on a CM5 sensor chip using the amine coupling kit
(both Cytiva). Analogously, GST alone was immobilized in the reference flow cell.
Drg1 was purified as described and eluted in elution buffer (20 mM HEPES-KOH,
150 mM KOAc, 5 mM Mg(OAc)2, 0.1% Tween-20, 1 mM DTT, pH 6.8) which was
also used as running buffer. 2 µM Drg1 was supplemented with 1 mM ATPγS and
injected several times with or without 200 µg/ml diazaborine. Each injection cycle
was composed of 120 s association, 180 s dissociation, and 60 s regeneration of the
surface with 1M NaCl. For the quantification of the complex half-life, the maximal
response at the beginning of the dissociation phase was set to 100% and the
dissociation was plotted over the time. Four independent injections from two
biological replicates (n= 4) were used to calculate the half-life by fitting the data
with a one-phase exponential decay curve in Graphpad prism.
Random mutagenesis of DRG1 and screening for diazaborine resistant
mutants. To screen for mutations evoking resistance to diazaborine, the DRG1
coding sequence (CDS) was amplified by PCR in the presence of 0.05 mM MnCl2
to randomly introduce mutations. The mutagenized PCR products were cloned
into a pRS315-DRG1 plasmid by fragment swapping prior to transformation of a
haploid shuffle strain carrying wild-type DRG1 on a URA plasmid (pRS316). The
resulting plasmids contained the full-length DRG1 CDS with its endogenous
promoter. After shuffling out of the pRS316-DRG1 plasmids on SD-agar plates
containing 1 g/l 5-FOA, the colonies were replica-plated on YPD agar plates
containing 100 µg/ml diazaborine to select for a diazaborine resistant phenotype.
Colonies growing on diazaborine containing agar plates were selected, plasmids
were extracted, sequenced to identify mutations within DRG1, and re-transformed
into the shuffle strain. After shuffling, the strains containing the mutant drg1 alleles
on pRS315 plasmids were used for spot assays. For protein expression, the mutant
drg1 alleles were subcloned into pCUP1 plasmids prior to transformation of the
BY4743 DRG1/drg1 expression strain. Primers are listed in Supplementary Table 5.
Spot assay. DRG1 shuffle strains transformed with pRS315 (LEU2) plasmids
carrying the respective mutant drg1 alleles under control of the endogenous pro-
moter were cultivated in SD-leu medium and spotted in serial dilutions on YPD
plates containing different concentrations of diazaborine (0–100 µg/ml) using a
metal stamp. The plates were incubated at 30 °C for up to 6 days.
Determination of the half-maximal inhibitory concentration (MIC) of diaza-
borine. The shuffle strains expressing the indicated mutant alleles were grown
overnight in liquid YPD medium. Afterward, fresh YPD medium containing
increasing concentrations of diazaborine (0–125 µg/ml) was inoculated to an initial
OD600 of 0.01 from these cultures and incubated for 48 h at 30 °C and 170 rpm. For
each strain, two biological replicates were measured with two technical replications.
Data were prepared and normalized to the untreated control in Microsoft Excel 2019.
Subsequently, calculation of the IC50 was performed by plotting the final OD600 over
the inhibitor concentration and non-linear regression fitting using the Graphpad
Prism software v3.03. The MICs are depicted as means with standard deviations.
ATPase activity measurement (Malachite green phosphate assay). The Drg1
ATPase activity was measured using the Malachite green phosphate assay
(ref. 57, Bioassay Systems) as reported previously19,21. Essentially, purified
proteins (Drg1 wild-type and mutant variants) were eluted in 20 mM HEPES-
KOH, 150 mM KOAc, 5 mM Mg(OAc)2, 0.1% Tween-20, 1 mM DTT, pH 6.8).
HIS-tagged Rlp24C was heterologously expressed in E. coli and purified exactly
as described in ref. 21. Purified Drg1 was incubated with 1 mM ATP and the
released phosphate was quantified using the malachite green phosphate assay kit.
The absorbance of the samples at 600 nm was measured at a GeniusPro
TECANTM plate reader with an associated Microsoft Excel plugin (XFluor4
v4.51) for data collection. The activity of 10 µg Drg1 (wild type) with 1 mM ATP
was measured either alone (=basal activity) or in the presence of 2 µg (1.68 µM)
His-Rlp24C. To indicated samples (+Dia), diazaborine was added to a final
concentration of 100 µg/ml (370 µM). The specific activity (µmol ATP/h/mg
Drg1) of all samples was normalized to the Drg1 basal activity in Microsoft Excel
2019 to display relative activities. For each protein at least two biological
replicates were measured with three technical replicates each to determine the
mean and standard deviation.
Differential scanning fluorimetry. DSF measurements of purified Drg1 were
performed as described21. The proteins were eluted in 20 mM HEPES-KOH, 150
mM KOAc, 5 mMMg(OAc)2, 1 mM DTT, pH 7.0. Eluted Drg1 was incubated with
1 mM ATP and increasing concentrations of diazaborine (6.25–200 µg/ml) prior to
the addition of the Sypro orange dye (Sigma-Aldrich, final 1:1000 dilution in
elution buffer). The samples were heated up from 25 to 95 °C in a Corbett Rotor-
Gene Series 6000 Realtime-Thermocycler with software version 1.7 under constant
fluorescence measurement (excitation 470 nm/emission 555 nm). The first deri-
vative (dF/dt) of the resulting melting curve was used to calculate the melting point
Tm (in °C). The ΔTm values were then calculated in Microsoft Excel 2019 and
plotted over the inhibitor concentration to calculate the dissociation constant KD
using the GraphPad Prism software and non-linear regression (one-site binding
hyperbola). Each protein variant was measured with at least two biological repli-
cates with two technical replicates each. To test the effect of the nucleotide ribose
2′-OH group on inhibitor binding, dATP or ATP were added at a final con-
centration of 5 mM and diazaborine was added at a concentration of 200 µg/ml
(740 µM).
Multiple sequence alignment. Multiple sequence alignments were performed
using ClustalW58 and colored using Jalview59. The graphical representation of the
alignment shown in Fig. 4e was generated using Weblogo60.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The data that support this study are available from the corresponding authors upon
reasonable request. Structural data generated in this study were deposited in the PDB
with accession code 7NKU and EMDB with accession code: EMD-12448. The raw
data (unprocessed micrographs) are deposited in the EMPIAR database accession
code 10717. Additional previously published datasets used for analyses in this study
are available from the PDB: 6OPC, 5FTJ, 5FTN, and 5X4L. The Cdc48-based
homology model of Drg1 is available upon request. Source data are provided with
this paper.
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